Email updates

Keep up to date with the latest news and content from Genome Medicine and BioMed Central.

Journal App

google play app store
Highly Accessed Open Badges Research highlight

Next-generation personalized drug discovery: the tripeptide GHK hits center stage in chronic obstructive pulmonary disease

Silke Meiners and Oliver Eickelberg*

Author Affiliations

Comprehensive Pneumology Center, University Hospital of the Ludwig-Maximilians-University Munich and Helmholtz Zentrum München, Member of the German Center for Lung Research, Max-Lebsche-Platz 31, D-81377 Munich, Germany

For all author emails, please log on.

Genome Medicine 2012, 4:70  doi:10.1186/gm371

Published: 21 September 2012


Chronic lung diseases (CLDs), including chronic obstructive pulmonary disease (COPD), are the second leading cause of death worldwide. The first report of database-driven drug discovery in carefully phenotyped COPD specimens has now been published in Genome Medicine, combining gene expression data in defined emphysematous areas with connectivity-map-based compound discovery. This joint effort may lead the way to novel and potentially more efficient concepts of personalized drug discovery for COPD in particular, and CLD in general.

See research article webcite